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ABSTRACT 
Viral infections are the most common type of infection in humans. Lung 
transplantation (LTx) recipients are exceptionally susceptible to infections in general, 
and the short- and long- term effects tend to be more detrimental. It is important to 
better determine the effects and outcomes of viral infections to improve survival and 
long-term quality of life after LTx. The following hypotheses were tested: that early 
viral respiratory tract infection (VRTI) has long term effect on outcome after lung 
transplantation (Papers I and III); that hepatitis E (HEV) antibodies are common in 
Swedish lung transplant recipients (Paper II); and that torque teno virus (TTV) and 
Epstein-Barr virus (EBV) may be potential biomarkers for monitoring of the net state 
of immunosuppression after LTx. 
Methods: Bronchiolar lavage (BAL) samples from a retrospective cohort (Paper I) and 
from a prospective cohort, together with nasopharyngeal (NPH) samples (Paper III) 
were analyzed with a multiplex PCR for respiratory viruses. Prospectively collected 
blood samples were analyzed for HEV antibodies using two ELISA methods (Paper 
II) and for TTV and EBV using PCR (paper IV).  
Results: VRTI during the first year was associated with a shortened time to chronic 
rejection but not to death in both the retrospective cohort and the prospective cohort 
(Paper I and III). Thirteen per cent of the patients had anti-HEV antibodies during 
follow-up. No association between TTV DNA nor EBV DNA and 
immunosuppression-related events could be found. 
Conclusions: VRTI during the first year is an independent risk factor for chronic 
rejection. HEV antibodies are equally common in the LTx population and the general 
Swedish population. EBV DNA and TTV DNA have limited usefulness as biomarkers 
for monitoring of immunosuppression after lung transplantation. 
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